DRUG · Unmapped registry intervention
MCLA-129
Find medicine records ·
Find other trials using this name
Clinical trial
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877
Study summary
ClinicalTrials.govPhase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Osimertinib
Normalized identity: osimertinib View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Chemotherapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Non-Small Cell Lung Cancer Metastaticunresolved
Gastric Cancerverified · MONDO: gastric cancer
Colorectal Cancerverified · MONDO: colorectal cancer
Interventions
Sponsors & collaborators
Merus B.V.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04868877 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.